Sexual desire

Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

Retrieved on: 
Tuesday, November 1, 2022
Cream, Failure, Vulva, Arousal, CEO, Health, Potential, Menopause, PRO, Sex, SST, Sexual arousal disorder, SEC, GLOBE, 8-K, Health minister, Risk, COVID-19, Sexual desire, Intellectual property, Trial of the century, Fertility, Progesterone, Drug, FSAD, Organon, Safety, Vasodilation, ED, Form, NASDAQ, Social media, Investor, Review, Woman, FDA, Bacterial vaginosis, Patient, Man, Prevalence, Birth, RESPOND, Erectile dysfunction, Forward-looking statement, HSDD, Female, Vagina, Solution, Pharmaceutical industry, Sex industry, Birth control, Bayer

SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that subject screening for the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% is complete, allowing for a topline data announcement target of 2Q-2023. The Phase 2b RESPOND clinical study is a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD). A total of approximately 100 subjects have completed all study assessments to date and, based on the subjects that have completed screening, a total of approximately 160 to 170 subjects are expected to complete the study for inclusion in the topline data assessment targeted for 2Q-2023.

Key Points: 
  • The Phase 2b RESPOND clinical study is a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD).
  • Sildenafil Cream is a proprietary topical formulation of sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, being developed as a first-in-category option for the treatment of FSAD.
  • We look forward to evaluating the topline data next year, said Sabrina Martucci Johnson, President and CEO of Dar Bioscience.
  • Increasing blood flow to the genital tissue, as Sildenafil Cream is designed to do, has the potential to improve genital arousal response and overall sexual experience for women.

EQS-News: Jupiter Wellness’s Potential New OTC Drug Could Put Some More Joy Back Into Breast Cancer Survivors’ Lives

Retrieved on: 
Saturday, October 22, 2022
News, Personal lubricant, Sexual desire, Female, American Cancer Society, Woman, Survivor, Research report, Attention, PFE, Breast augmentation, Bristol-Myers Squibb Co. v. Superior Court, NYSE, NASDAQ, Patient, Galena Biopharma, Contract, Research, Man, Pfizer, Breast, International Agency for Research on Cancer, Hair loss, Sensation, Burns, History, Merck, Technology, Eye, Manifest and latent functions and dysfunctions, Lung cancer, Human, Health, BMY, US, Libido, Health minister, Breast cancer, Safety, Sexual arousal, OTC, Advertising, Organic, Skin, Intellectual property, Dermatitis, Ageing, MRK, Male, Dietary supplement, Medical imaging, Birth control, Pharmaceutical industry, Cancer

In 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S.

Key Points: 
  • In 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S.
  • Breast cancer affects men, too, and about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022 with a mans lifetime risk of breast cancer being about 1 in 833.
  • About 85% of breast cancers occur in women who have no family history of breast cancer.
  • Yet the adverse effects of cancer treatment continue to cause concern and unhappiness for breast cancer survivors.

DGAP-News: It All Comes Down To Science And Research With The Efficacy Of Jupiter Wellness’s Lineup Of Skin And Hair Treatment Drugs

Retrieved on: 
Tuesday, September 6, 2022
CBD, Pachydactylus labialis, Burns, Patient, Breast cancer, Burn, Advertising, Female, NYSE, OTC, Sexual desire, Research, Hair, NASDAQ, Amazon (company), Pfizer, PFE, Food and Drug Administration, Man, Vitiligo, Sale, Walmart, Food, Skin, Herpes labialis, Psoriasis, Pleasure, Simplex, Dermatitis, WMT, Social media, FDA, Mouth, Atopic dermatitis, Hair loss, Skin care, Intellectual property, Woman, Minoxidil, Health, Biology, AMZN, Cosmetics, Pharmaceutical industry, Petroleum jelly, Dietary supplement, Crisaborole

Jupiter Wellness Inc. (NASDAQ: JUPW), which focuses on making drugs and skin- and hair-care products, is riding on this emerging trend.

Key Points: 
  • Jupiter Wellness Inc. (NASDAQ: JUPW), which focuses on making drugs and skin- and hair-care products, is riding on this emerging trend.
  • Jupiters development pipeline includes products to address psoriasis, eczema, burns, herpes and cold sores, hair loss and female libido loss.
  • It reportedly works by enriching the sulfotransferase enzyme in the hair and amping up the efficacy of Minoxidil for hair loss.
  • I am pleased to report that Jupiter Wellness is on track with its 2022 roadmap, Jupiter Wellness CEO Brian John said.

Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Retrieved on: 
Monday, August 29, 2022
Cream, COVID-19, CEO, Safety, Female, Health minister, Bacterial vaginosis, SAN, SST, NASDAQ, Erectile dysfunction, Solution, Man, 8-K, ED, Vasodilation, Sex, Birth, SEC, Review, Menopause, Sexual desire, Progesterone, HSDD, GLOBE, Fertility, Prevalence, Vulva, FSAD, FDA, Arousal, Social media, PRO, RESPOND, Failure, Twitter, Form, Investor, Risk, Vagina, Organon, Intellectual property, Woman, Health, Sexual arousal disorder, Forward-looking statement, Trial of the century, Patient, Pharmaceutical industry, Sex industry, Birth control, Bayer

SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that, based on the results of an interim analysis to evaluate the relative magnitude of the treatment effect, they expect to complete enrollment in the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in 4Q-2022, allowing for a topline data announcement target of 2Q-2023. The interim analysis was conducted by an independent third-party statistical resource and both Daré and SST continue to remain blinded to results of the study by treatment group. The Phase 2b RESPOND clinical study is a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD).

Key Points: 
  • The interim analysis was conducted by an independent third-party statistical resource and both Dar and SST continue to remain blinded to results of the study by treatment group.
  • The Phase 2b RESPOND clinical study is a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD).
  • Completing this Phase 2b study will be a significant milestone in the development of what has the potential to be the first FDA-approved product to treat FSAD.
  • FSAD is distinct from hypoactive sexual desire disorder (HSDD) in women, which is characterized primarily by a lack of sexual desire.

De Rankin Uses OnlyFans Account to Destigmatize Sexual Desires and Understand Relationship Satisfaction

Retrieved on: 
Tuesday, August 9, 2022
Woman, Meditation, Psychology, Mental health, Shame, OnlyFans, COVID, Harvard University, Cardi B, Research, Life, Man, Judgement, Yoga, Coronavirus, Sexual desire, Insurance, Friends, Management, Birth control, Medicine, Nursing

In order to better understand the depth of the ability of authenticity to cause relationship dissatisfaction De began on Only Fans page.

Key Points: 
  • In order to better understand the depth of the ability of authenticity to cause relationship dissatisfaction De began on Only Fans page.
  • While gathering information on her relationships and desires the page quickly blossomed into a multi-million-dollar venture.
  • De runs her Only Fans account alongside her current position as the Director of Nursing for a large insurance company.
  • For De, it's another job well done; for her clients, it's an emboldening experience that can help to further their relationship and boost satisfaction.

Rosebud Woman Shares New Study on Women's Attitudes Towards Sexual Health and Intimate Wellness in Perimenopause, Menopause and Beyond

Retrieved on: 
Thursday, March 31, 2022
Dry, Partner, NEW, Sexual desire, Sex, Confusion, Friends, Human, Sensation, Woman, Millennials, Arousal, Candidiasis, Urinary tract infection, Solution, STI, Relaxation, Menopause, Instagram, Book, Sex industry, Birth control, Orgasm, Endometriosis

NEW YORK, March 31, 2022 /PRNewswire-PRWeb/ -- Intimate Wellness pioneer, Rosebud Woman shares the results from a recent survey of nearly 400 women between the ages of 28 and 79. The survey covers a range of questions, including mind, body and spirit concerns around sexuality throughout the stages of a woman's reproductive life.

Key Points: 
  • NEW YORK, March 31, 2022 /PRNewswire-PRWeb/ -- Intimate Wellness pioneer, Rosebud Woman shares the results from a recent survey of nearly 400 women between the ages of 28 and 79.
  • The Partner Gap: 94% of respondents in perimenopause, menopause or beyond are sexually active or would like to be.
  • To learn more about how women's intimate health, and how cultural attitudes towards sensuality, sexuality and reproductive impact women's lives, visit rosewoman.com to receive a summary of study results.
  • Rosebud Woman is a pioneer in women's intimate wellness and body care.

Rosy Launches Personalized Wellness Plans for Women's Sexual Health

Retrieved on: 
Monday, February 14, 2022
Sexual desire, Embarrassment, Arousal, Patient, Orgasm, Time, CEO, Mount Sinai Hospital, Community, Man, FACOG, Obstetrics and gynaecology, Solution, Wellness, Health minister, CBT, Woman, Privacy, IF, Lubrication, Research, Program, Face, Birth control, Sex industry, Rosy

When signing up for Rosy, women take a comprehensive Sexual Wellness Quiz, netting out with an evidence-based, guided path to optimal sexual wellbeing.

Key Points: 
  • When signing up for Rosy, women take a comprehensive Sexual Wellness Quiz, netting out with an evidence-based, guided path to optimal sexual wellbeing.
  • In her busy Ob/Gyn practice, she came across many patients with sexual health questions and concerns that had often gone unaddressed.
  • "Over the last 3 years, Rosy has allowed us to look at women's sexual health in a way that has never been done before.
  • Rosy is a first-of-its-kind app and media platform that offers personalized solutions for women's sexual wellness.

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

Retrieved on: 
Thursday, January 6, 2022
BD, Caregiver, Family, Lists of diseases, Knowledge, Grammatical mood, ALKS, The Harris Poll, Harris, Alkermes (company), Research, Education, Depression, Bipolar I disorder, Adult, Social support, Intention, Neurodegeneration, Cancer, Uncertainty, Life, Motivation, Medical Affairs Bureau, Sexual desire, Ageing, Annual report, Neurological disorder, Risk, DBSA, Private Securities Litigation Reform Act, Disease, Awareness, Hope, SEC, Mania, Disorder, Decision-making, Public relations, Schizophrenia, Somnolence, Diagnosis, Weight gain, Population, Nasdaq, National Comorbidity Survey, Prevalence, Anxiety, Mood disorder, Multimedia, U.S. Securities and Exchange Commission, Bipolar disorder, Friends, Pharmaceutical industry, Risk management, Health insurance, Alkermes

Despite the challenges that some people living with BD-I face in their treatment journey, many respondents (75%) reported feeling well-managed on their then-current BD-I medication regimen.

Key Points: 
  • Despite the challenges that some people living with BD-I face in their treatment journey, many respondents (75%) reported feeling well-managed on their then-current BD-I medication regimen.
  • The results of this survey do not necessarily represent the experiences of the broader population of people living with BD-I.
  • Bipolar disorder is a brain disorder that is marked by extreme changes in a person's mood, energy and ability to function.
  • Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication.

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

Retrieved on: 
Thursday, January 6, 2022
BD, Caregiver, Family, Lists of diseases, Knowledge, Grammatical mood, ALKS, The Harris Poll, Harris, Alkermes (company), Research, Education, Depression, Bipolar I disorder, Adult, Social support, Intention, Neurodegeneration, Cancer, Uncertainty, Life, Motivation, Medical Affairs Bureau, Sexual desire, Ageing, Annual report, Neurological disorder, Risk, DBSA, Private Securities Litigation Reform Act, Disease, Awareness, Hope, SEC, Mania, Disorder, Decision-making, Public relations, Schizophrenia, Somnolence, Diagnosis, Weight gain, Population, Nasdaq, National Comorbidity Survey, Prevalence, Anxiety, Mood disorder, U.S. Securities and Exchange Commission, Bipolar disorder, Friends, Pharmaceutical industry, Risk management, Health insurance, Alkermes

DUBLIN, Jan. 6, 2022 /PRNewswire/ -- Results from a newly released survey provide insights from adults living with bipolar I disorder (BD-I)* in the United States (U.S.) on the burden of living with this serious mental health condition and their experiences with treatment. This research was conducted in support of Alkermes' commitment to understanding the unique needs of people living with BD-I and supporting increased disease awareness and education. 

Key Points: 
  • Despite the challenges that some people living with BD-I face in their treatment journey, many respondents (75%) reported feeling well-managed on their then-current BD-I medication regimen.
  • The results of this survey do not necessarily represent the experiences of the broader population of people living with BD-I.
  • Bipolar disorder is a brain disorder that is marked by extreme changes in a person's mood, energy and ability to function.
  • Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication.

Dating app Feeld announces minimum salary of $80,000 for all employees

Retrieved on: 
Wednesday, November 24, 2021
People, Confusion, Freedom, Workplace, Human, CEO, NEW, Fear, Multimedia, Sexual desire, VP, Growth, Management

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Today, Feeld -the world's most progressive dating app- announces all employees across the globe will be receiving a minimum salary of $80,000 (£60,000*) from January 2022.

Key Points: 
  • A first for the dating app industry, the Baseline Freedom Salary is the latest example of the transparent compensation system across the business
    NEW YORK, Nov. 24, 2021 /PRNewswire/ --Today, Feeld -the world's most progressive dating app- announces all employees across the globe will be receiving a minimum salary of $80,000 (60,000*) from January 2022.
  • We feel it's crucial all of our employees live meaningful and fulfilling life and fair compensation is key.
  • The Baseline Freedom Salary also reflects how the humans who work at Feeld respect and value each others' work."
  • Feeld is the world's most progressive dating app with over 20 sexuality and gender options.